PROCEPT BioRobotics Corp (PRCT) financials: revenue, earnings and cash flow
Fiscal 2020–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
PROCEPT BioRobotics’s revenue went from $8M in fiscal 2020 to $308M in fiscal 2025, growth of about 109.0% a year.
Net income in fiscal 2025 was -$96M, a net margin of -31.0%; the best year in this period was 2020 with -$53M.
Over the twelve months to September 30, 2026, revenue was $352M and net income -$115M.
Free cash flow was -$58M in fiscal 2025 and positive in 0 of the 6 years shown.
The diluted share count rose 1416% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $352M | $308M | $224M | $136M | $75M | $34M | $8M |
| Gross profit | $228M | $196M | $137M | $71M | $37M | $16M | -$1M |
| Operating income | -$118M | -$104M | -$97M | -$109M | -$81M | -$54M | -$48M |
| Net income | -$115M | -$96M | -$91M | -$106M | -$87M | -$60M | -$53M |
| EPS (diluted) | $-2.02 | $-1.72 | $-1.75 | $-2.24 | $-1.96 | $-3.63 | $-14.47 |
| R&D | $81M | $71M | $62M | $48M | $29M | $19M | $16M |
| Revenue growth | — | +37.2% | +64.8% | +81.5% | +117.6% | +346.7% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$77M | -$49M | -$99M | -$108M | -$80M | -$57M | -$48M |
| Capital spending | -$8M | -$9M | -$4M | -$25M | -$3M | -$592000 | -$233000 |
| Free cash flow | -$85M | -$58M | -$104M | -$133M | -$83M | -$58M | -$49M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — |
| Stock-based pay | $54M | $48M | $32M | $19M | $10M | $4M | $2M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash | — | $287M | $334M | $257M | $222M | $304M | $100M |
| Debt | — | $78M | $80M | $79M | $77M | $54M | $55M |
| Equity | — | $366M | $402M | $281M | $197M | $267M | -$183M |
| Total assets | — | $508M | $534M | $405M | $309M | $337M | $126M |
| Shares (diluted) | 57M | 56M | 52M | 47M | 44M | 16M | 4M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Gross margin | 64.7% | 63.7% | 61.1% | 52.2% | 49.4% | 46.0% | -16.3% |
| Operating margin | -33.6% | -33.7% | -43.0% | -80.2% | -107.6% | -157.1% | -619.4% |
| Net margin | -32.6% | -31.0% | -40.7% | -77.8% | -116.2% | -173.6% | -687.0% |
| FCF margin | -24.1% | -18.9% | -46.2% | -97.8% | -110.7% | -168.0% | -629.5% |
| ROIC | — | -18.5% | -15.8% | -24.0% | -23.2% | -13.3% | — |
| ROE | — | -26.1% | -22.7% | -37.7% | -44.2% | -22.4% | 29.0% |
Frequently asked questions
What is PROCEPT BioRobotics’s annual revenue?
$308M in fiscal 2025 and $352M over the twelve months to September 30, 2026.
How much profit does PROCEPT BioRobotics make?
Net income was -$96M in fiscal 2025 (net margin -31.0%).
Is PROCEPT BioRobotics’s revenue growing?
Yes: revenue rose 37.2% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.